OMDA Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $88 million, up 43% year-over-year and 13% sequentially from Q1.

Gross Margin: 73% on a GAAP basis (up from 66% YoY) and 74% on a non-GAAP basis (up from 68% YoY).

Net Income: $5 million, marking the second consecutive quarter of GAAP profitability, compared to a loss of $5 million in Q2 2025.

Adjusted EBITDA: $11 million, a record for the company, improving by $11 million YoY.

Membership Growth: Total members reached approximately 1.1 million, up 45% year-over-year.

Revenue per Member: $284, slightly up from $279 YoY.

2Strategic Updates and Business Highlights

Omada Health reported its strongest quarter ever, with record membership and revenue.

Transition of leadership announced: Wei-Li Shao will become CEO in January 2027, with Sean Duffy moving to Executive Chair.

Strong momentum in commercial relationships, including partnerships with leading pharmacy benefit managers (PBMs) and expansion with Health Care Service Corporation (HCSC), adding 1.5 million covered lives.

New product launches include a cholesterol program and enhancements to GLP-1 offerings, which are expected to drive further growth.

AI integration is enhancing operational efficiency, contributing to a 10% reduction in cost to serve members.

3Forward Guidance and Outlook

Full-year revenue guidance raised to $334 million-$340 million, up from previous guidance of $322 million-$330 million.

Adjusted EBITDA guidance raised to $21 million-$27 million, up from $14 million-$20 million.

Anticipated moderation in year-over-year growth rates in the second half of 2026 due to typical seasonality and a strong first half performance.

4Bad News, Challenges, or Points of Concern

Potential headwinds include the uncertainty surrounding employer decisions on GLP-1 coverage, which may impact future growth.

The company expects a more normalized growth trajectory in the second half of 2026 compared to the exceptionally strong first half.

Competitive pressures from other digital health companies and evolving employer attitudes towards chronic disease management could pose risks.

5Notable Q&A Insights

AI is seen as a critical driver of operational leverage, improving member engagement and reducing costs.

The company is experiencing broad-based growth across its product offerings, not just limited to GLP-1s, which counters perceptions of dependency on a single product line.

The expansion with HCSC is expected to yield revenue starting in H1 2027, reflecting the embedded nature of their programs in fully insured plans.

Questions raised about the dynamics of GLP-1 coverage suggest that employers are evaluating their coverage strategies, which could impact future enrollments and revenue.

Omada's ability to report on member outcomes and engagement metrics is a key selling point for their partnerships with PBMs and employers, enhancing their value proposition. Overall, Omada Health demonstrated strong financial performance and strategic positioning, but faces challenges related to market dynamics and competitive pressures that could impact future growth.